Novartis' Key Drug Del-Desiran Fails Phase 3 Trial, Stock Drops Over 5%
nashnova research
Del-desiran — the crown asset of Novartis's $12 billion Avidity acquisition — missed its primary endpoint in a pivotal late-stage trial, the company's third clinical setback in a single week, sending shares down as much as 5.1% in early trading.
Why does this one drug matter so much?
Del-desiran came with the $12 billion Avidity Biosciences acquisition and was the deal's centrepiece. CEO Vas Narasimhan told Bloomberg TV its "peak sales potential exceeds $5 billion."
A positive readout would have made it the first drug ever to demonstrate efficacy in myotonic dystrophy type 1 — a rare genetic disorder that causes muscles to progressively weaken and lock up.
This means → the failure is not a routine pipeline miss. It is the collapse of a strategic, billion-dollar bet.
What exactly went wrong in the trial?
The primary endpoint was a "rapid hand-opening" test — how quickly patients can unclench their fist, measuring muscle stiffness. The drug arm showed no significant difference versus placebo.
In plain terms = patients on the drug opened their hands no faster than those on a sugar pill — the benefit was not proven.
Novartis said it will analyse the full dataset and consult regulators before deciding next steps, but offered no concrete timeline.
Three clinical setbacks in one week — what happened?
In the same week, Novartis halted an experimental cell therapy for autoimmune disease after three patient deaths.
Cardiac drug pelacarsen also failed in a closely watched study.
The sole bright spot: a positive result for an experimental multiple-sclerosis drug — not enough to offset three consecutive pipeline blows.
How are the market and analysts reacting?
Novartis shares fell as much as 5.1% on Tradegate versus the Zurich close after the news broke.
Vontobel analyst Stefan Schneider called it a "major pipeline setback" and said it "lowers our confidence in the other therapies Novartis acquired through Avidity." He maintained a hold rating.
This reflects a deeper concern: the market is not just pricing in one drug's failure — it is re-rating the expected return on the entire $12 billion acquisition.
What is the most critical question going forward?
Novartis faces the largest patent cliff in its history — blockbuster drugs losing exclusivity, opening the door to generics and sharp revenue declines — and urgently needs new growth drivers.
With del-desiran gone, whether the remaining Avidity pipeline assets can justify the $12 billion price tag becomes the market's central unresolved question.
This means → every future clinical data readout from the Avidity pipeline will be judged through a single lens: "Was this acquisition worth it?"
市场有风险，内容仅供研究参考，不构成投资建议。